Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IO Biotech (IOBT)
NASDAQ:IOBT
IOBT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $1.85
Previous CloseN/A
Volume57.25K
Average Volume (3M)124.20K
Market Cap
$73.13M
Enterprise Value-$8.99M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Mar 27, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding65,880,910
10 Day Avg. Volume104,384
30 Day Avg. Volume124,202
Standard Deviation0.22
R-Squared0.00288
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.89
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$8.00Price Target Upside620.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
IO Biotech News
PremiumCompany Announcements
IO Biotech Secures €57.5 Million EIB Loan Facility
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressEnrollment in the Ph2 adjuvant/neoadjuvant basket trial in melanoma and HNSCC is progressing ahead of expectations.
Efficacy Of TreatmentThe updated data presented at ESMO and SITC from the fully enrolled HNSCC and NSCLC Ph2 basket trial cohorts continued to show favorable efficacy.
Financial OutlookEnded 3Q24 with $80.2M in cash, which is expected to support operations into 4Q25.
Bears Say
Clinical Trial UncertaintyThe interim results from the Phase 3 study did not meet statistical significance, and there is uncertainty regarding the numerical benefit in the treatment arm as the ORR numbers were not disclosed.
Safety ConcernsThe safety profile showed Grade 3-4 treatment-related adverse events in 24% of patients, which is slightly higher than some comparable studies.
Treatment DiscontinuationThe treatment-related discontinuations were higher at 16% compared to a lower rate in other studies.
---
Ownership Overview
28.12% Insiders
0.35% Mutual Funds
21.16% Other Institutional Investors
50.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IOBT FAQ
What was IO Biotech’s price range in the past 12 months?
IO Biotech lowest stock price was $0.66 and its highest was $1.85 in the past 12 months.
What is IO Biotech’s market cap?
IO Biotech’s market cap is $73.13M.
When is IO Biotech’s upcoming earnings report date?
IO Biotech’s upcoming earnings report date is Mar 27, 2025 which is in 34 days.
How were IO Biotech’s earnings last quarter?
IO Biotech released its earnings results on Nov 12, 2024. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.288 by -$0.072.
Is IO Biotech overvalued?
According to Wall Street analysts IO Biotech’s price is currently Undervalued.
Does IO Biotech pay dividends?
IO Biotech does not currently pay dividends.
What is IO Biotech’s EPS estimate?
IO Biotech’s EPS estimate is -0.39.
How many shares outstanding does IO Biotech have?
IO Biotech has 65,880,910 shares outstanding.
What happened to IO Biotech’s price movement after its last earnings report?
IO Biotech reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.288. Following the earnings report the stock price went down -11.429%.
Which hedge fund is a major shareholder of IO Biotech?
Among the largest hedge funds holding IO Biotech’s share is RA Capital Management. It holds IO Biotech’s shares valued at 0.
---
IO Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (620.72% Upside)
$8.00 (620.72% Upside)
Blogger Sentiment
Bullish
IOBT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $54.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.84%
12-Months-Change
Fundamentals
Return on Equity
-78.50%
Trailing 12-Months
Asset Growth
-47.87%
Trailing 12-Months
Company Description
IO Biotech
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
---
IOBT Stock 12 Month Forecast
Average Price Target
$8.00
▲(620.72% Upside)
Technical Analysis
Agenus
―
Fate Therapeutics
―
Intra-Cellular Therapies
―
Blueprint Medicines
―
Adaptimmune Therapeutics
―
Best Analysts Covering IOBT
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-26.64%
assigned a buy rating 3 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -26.64% per trade.
---